BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002. [PMID: 27550547 DOI: 10.1038/srep32002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 124] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Akhtar I, Stewart FA, Härle A, Droste A, Beller M. Visualization of endogenous gut bacteria in Drosophila melanogaster using fluorescence in situ hybridization. PLoS One 2021;16:e0247376. [PMID: 33606846 DOI: 10.1371/journal.pone.0247376] [Reference Citation Analysis]
3 Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis 2021;20:22. [PMID: 33637088 DOI: 10.1186/s12944-021-01440-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Zhang X, Wu Q, Zhao Y, Aimy A, Yang X. Consumption of post-fermented Jing-Wei Fuzhuan brick tea alleviates liver dysfunction and intestinal microbiota dysbiosis in high fructose diet-fed mice. RSC Adv 2019;9:17501-13. [DOI: 10.1039/c9ra02473e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
5 Proffitt C, Bidkhori G, Moyes D, Shoaie S. Disease, Drugs and Dysbiosis: Understanding Microbial Signatures in Metabolic Disease and Medical Interventions. Microorganisms 2020;8:E1381. [PMID: 32916966 DOI: 10.3390/microorganisms8091381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Reference Citation Analysis]
7 Wang L, Jiao T, Yu Q, Wang J, Wang L, Wang G, Zhang H, Zhao J, Chen W. Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis. Biomedicines 2022;10:84. [DOI: 10.3390/biomedicines10010084] [Reference Citation Analysis]
8 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
9 Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese vs lean subjects. PLoS One. 2019;14:e0213692. [PMID: 30870486 DOI: 10.1371/journal.pone.0213692] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
10 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
13 Quesada-Vázquez S, Aragonès G, Del Bas JM, Escoté X. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. Cells 2020;9:E176. [PMID: 31936799 DOI: 10.3390/cells9010176] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
14 Schutte S, Esser D, Hoevenaars FPM, Hooiveld GJEJ, Priebe MG, Vonk RJ, Wopereis S, Afman LA. A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects. The American Journal of Clinical Nutrition 2018;108:1264-74. [DOI: 10.1093/ajcn/nqy204] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
15 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
16 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
18 Akhmedov VA, Gaus OV. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Terapevticheskii arkhiv 2019;91:143-8. [DOI: 10.26442/00403660.2019.02.000051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66:1727-1738. [PMID: 28586116 DOI: 10.1002/hep.29306] [Cited by in Crossref: 254] [Cited by in F6Publishing: 212] [Article Influence: 50.8] [Reference Citation Analysis]
20 Liu P, Jia XZ, Chen Y, Yu Y, Zhang K, Lin YJ, Wang BH, Peng GP. Gut microbiota interacts with intrinsic brain activity of patients with amnestic mild cognitive impairment. CNS Neurosci Ther 2021;27:163-73. [PMID: 32929861 DOI: 10.1111/cns.13451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
21 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time? J Gastroenterol Hepatol 2020;35:1969-77. [PMID: 32267559 DOI: 10.1111/jgh.15071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
24 Dalal P, Sharma D. Microbe defines the efficacy of chemotherapeutic drug: a complete paradigm. FEMS Microbiol Lett 2021;368:fnab116. [PMID: 34448860 DOI: 10.1093/femsle/fnab116] [Reference Citation Analysis]
25 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
26 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Vasques-Monteiro IML, Silva-Veiga FM, Miranda CS, de Andrade Gonçalves ÉCB, Daleprane JB, Souza-Mello V. A rise in Proteobacteria is an indicator of gut-liver axis-mediated nonalcoholic fatty liver disease in high-fructose-fed adult mice. Nutr Res 2021;91:26-35. [PMID: 34130208 DOI: 10.1016/j.nutres.2021.04.008] [Reference Citation Analysis]
29 Wang B, Zhu S, Li W, Tang Q, Luo H. Effects of chromium stress on the rhizosphere microbial community composition of Cyperus alternifolius. Ecotoxicol Environ Saf 2021;218:112253. [PMID: 33933813 DOI: 10.1016/j.ecoenv.2021.112253] [Reference Citation Analysis]
30 Armstrong H, Alipour M, Valcheva R, Bording-Jorgensen M, Jovel J, Zaidi D, Shah P, Lou Y, Ebeling C, Mason AL, Lafleur D, Jerasi J, Wong GK, Madsen K, Carroll MW, Huynh HQ, Dieleman LA, Wine E. Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases. Microbiome 2019;7:1. [PMID: 30606251 DOI: 10.1186/s40168-018-0604-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 18.7] [Reference Citation Analysis]
31 Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
32 Park E, Jeong JJ, Won SM, Sharma SP, Gebru YA, Ganesan R, Gupta H, Suk KT, Kim DJ. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. Cells 2021;10:2634. [PMID: 34685614 DOI: 10.3390/cells10102634] [Reference Citation Analysis]
33 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
34 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
35 Ranade AV, Shirolkar A, Pawar SD. Gut microbiota: One of the new frontiers for elucidating fundamentals of Vipaka in Ayurveda. Ayu 2019;40:75-8. [PMID: 32398906 DOI: 10.4103/ayu.AYU_210_18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
36 Miao ZH, Zhou WX, Cheng RY, Liang HJ, Jiang FL, Shen X, Lu JH, Li M, He F. Dysbiosis of intestinal microbiota in early life aggravates high-fat diet induced dysmetabolism in adult mice. BMC Microbiol 2021;21:209. [PMID: 34238228 DOI: 10.1186/s12866-021-02263-6] [Reference Citation Analysis]
37 Porras D, Nistal E, Martínez-Flórez S, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front Physiol 2018;9:1813. [PMID: 30618824 DOI: 10.3389/fphys.2018.01813] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
38 John OD, Mouatt P, Majzoub ME, Thomas T, Panchal SK, Brown L. Physiological and Metabolic Effects of Yellow Mangosteen (Garcinia dulcis) Rind in Rats with Diet-Induced Metabolic Syndrome. Int J Mol Sci 2019;21:E272. [PMID: 31906096 DOI: 10.3390/ijms21010272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
39 Lee Y, Lee HY. Revisiting the Bacterial Phylum Composition in Metabolic Diseases Focused on Host Energy Metabolism. Diabetes Metab J. 2020;44:658-667. [PMID: 32662252 DOI: 10.4093/dmj.2019.0220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease. J Hepatol 2021:S0168-8278(21)01997-8. [PMID: 34437908 DOI: 10.1016/j.jhep.2021.08.003] [Reference Citation Analysis]
41 Bisht V, Acharjee A, Gkoutos GV. NFnetFu: A novel workflow for microbiome data fusion. Comput Biol Med 2021;135:104556. [PMID: 34216888 DOI: 10.1016/j.compbiomed.2021.104556] [Reference Citation Analysis]
42 Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu XO, Yu D. Sex-Specific Associations between Gut Microbiome and Non-Alcoholic Fatty Liver Disease among Urban Chinese Adults. Microorganisms 2021;9:2118. [PMID: 34683439 DOI: 10.3390/microorganisms9102118] [Reference Citation Analysis]
43 Gargari G, Deon V, Taverniti V, Gardana C, Denina M, Riso P, Guardamagna O, Guglielmetti S. Evidence of dysbiosis in the intestinal microbial ecosystem of children and adolescents with primary hyperlipidemia and the potential role of regular hazelnut intake. FEMS Microbiol Ecol 2018;94. [PMID: 29566154 DOI: 10.1093/femsec/fiy045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
44 Liu C, Wang YL, Yang YY, Zhang NP, Niu C, Shen XZ, Wu J. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J 2021;35:e21871. [PMID: 34473374 DOI: 10.1096/fj.202100939R] [Reference Citation Analysis]
45 Loman BR, Hernández-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev 2018;76:822-39. [PMID: 30113661 DOI: 10.1093/nutrit/nuy031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
46 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
47 Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci 2021;22:7800. [PMID: 34360566 DOI: 10.3390/ijms22157800] [Reference Citation Analysis]
48 Ghorbani Y, Schwenger KJP, Allard JP. Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes. Eur J Nutr 2021;60:2361-79. [PMID: 33651137 DOI: 10.1007/s00394-021-02520-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
50 Baumann A, Nier A, Hernández-Arriaga A, Brandt A, Lorenzo Pisarello MJ, Jin CJ, Pilar E, Camarinha-Silva A, Schattenberg JM, Bergheim I. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Sci Rep 2021;11:17815. [PMID: 34497333 DOI: 10.1038/s41598-021-97346-9] [Reference Citation Analysis]
51 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
52 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
53 Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67:534-548. [PMID: 28696585 DOI: 10.1002/hep.29359] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 25.8] [Reference Citation Analysis]
54 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
55 Xu P, Shi Y, Liu P, Yang Y, Zhou C, Li G, Luo J, Zhang C, Cao H, Hu G, Guo X. 16S rRNA gene sequencing reveals an altered composition of the gut microbiota in chickens infected with a nephropathogenic infectious bronchitis virus. Sci Rep 2020;10:3556. [PMID: 32103130 DOI: 10.1038/s41598-020-60564-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Reference Citation Analysis]
57 Liu Y, Xie C, Zhai Z, Deng ZY, De Jonge HR, Wu X, Ruan Z. Uridine attenuates obesity, ameliorates hepatic lipid accumulation and modifies the gut microbiota composition in mice fed with a high-fat diet. Food Funct 2021;12:1829-40. [PMID: 33527946 DOI: 10.1039/d0fo02533j] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Safari Z, Monnoye M, Abuja PM, Mariadassou M, Kashofer K, Gérard P, Zatloukal K. Steatosis and gut microbiota dysbiosis induced by high-fat diet are reversed by 1-week chow diet administration. Nutr Res 2019;71:72-88. [PMID: 31757631 DOI: 10.1016/j.nutres.2019.09.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
59 Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein Cell 2021;12:360-73. [PMID: 33346905 DOI: 10.1007/s13238-020-00814-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
60 Hyun CK. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:9139. [PMID: 34502047 DOI: 10.3390/ijms22179139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
62 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 33.7] [Reference Citation Analysis]
63 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
64 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sui G, Jia L, Quan D, Zhao N, Yang G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging (Albany NY) 2021;13:21309-24. [PMID: 34473644 DOI: 10.18632/aging.203460] [Reference Citation Analysis]
66 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
67 Mishra AK, Kumar SS, Ghosh AR. Probiotic Enterococcus faecalis AG5 effectively assimilates cholesterol and produces fatty acids including propionate. FEMS Microbiol Lett 2019;366:fnz039. [PMID: 30772890 DOI: 10.1093/femsle/fnz039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
68 Wang T, Guo XK, Xu H. Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota. Front Microbiol 2021;12:728823. [PMID: 34721326 DOI: 10.3389/fmicb.2021.728823] [Reference Citation Analysis]
69 Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults.Hepatology. 2021;73:968-982. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
70 Li Z, Ni M, Yu H, Wang L, Zhou X, Chen T, Liu G, Gao Y. Gut Microbiota and Liver Fibrosis: One Potential Biomarker for Predicting Liver Fibrosis. Biomed Res Int 2020;2020:3905130. [PMID: 32685479 DOI: 10.1155/2020/3905130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
72 Thavamani A, Salem I, Sferra TJ, Sankararaman S. Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis. Metabolites 2021;11:123. [PMID: 33671639 DOI: 10.3390/metabo11020123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Li W, Liu J, Cai J, Zhang XJ, Zhang P, She ZG, Chen S, Li H. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol 2021;163:118-32. [PMID: 34737121 DOI: 10.1016/j.yjmcc.2021.10.007] [Reference Citation Analysis]
74 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
75 Liu Y, Song X, Zhou H, Zhou X, Xia Y, Dong X, Zhong W, Tang S, Wang L, Wen S, Xiao J, Tang L. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Front Microbiol 2018;9:530. [PMID: 29623075 DOI: 10.3389/fmicb.2018.00530] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
76 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Li F, Sun G, Wang Z, Wu W, Guo H, Peng L, Wu L, Guo X, Yang Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci 2018;61:770-8. [PMID: 29948900 DOI: 10.1007/s11427-017-9303-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
78 Bolinger H, Tran D, Harary K, Paoli GC, Guron G, Namazi H, Khaksar R. Utilizing the Microbiota and Machine Learning Algorithms to Assess Risk of Salmonella Contamination in Poultry Rinsate. J Food Prot 2021. [PMID: 34015130 DOI: 10.4315/JFP-20-367] [Reference Citation Analysis]
79 Ghoshal UC, Baba CS, Ghoshal U, Alexander G, Misra A, Saraswat VA, Choudhuri G. Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian J Gastroenterol. 2017;36:390-399. [PMID: 29034439 DOI: 10.1007/s12664-017-0797-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
80 Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, Zhang L, Jia L, Yue S, Zhou K, Li L, Luo B, Wang B. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun 2019;80:633-43. [PMID: 31063846 DOI: 10.1016/j.bbi.2019.05.008] [Cited by in Crossref: 83] [Cited by in F6Publishing: 86] [Article Influence: 27.7] [Reference Citation Analysis]
81 Torres-Sánchez A, Pardo-Cacho J, López-Moreno A, Ruiz-Moreno Á, Cerk K, Aguilera M. Antimicrobial Effects of Potential Probiotics of Bacillus spp. Isolated from Human Microbiota: In Vitro and In Silico Methods. Microorganisms 2021;9:1615. [PMID: 34442694 DOI: 10.3390/microorganisms9081615] [Reference Citation Analysis]
82 Mohammadzadeh A, Roshanravan N, Mesri Alamdari N, Safaiyan A, Mosharkesh E, Hadi A, Barati M, Ostadrahimi A. The interplay between fasting, gut microbiota, and lipid profile. Int J Clin Pract 2021;:e14591. [PMID: 34227218 DOI: 10.1111/ijcp.14591] [Reference Citation Analysis]
83 Zha H, Chen Y, Wu J, Chang K, Lu Y, Zhang H, Xie J, Wang Q, Tang R, Li L. Characteristics of three microbial colonization states in the duodenum of the cirrhotic patients. Future Microbiol 2020;15:855-68. [PMID: 32662659 DOI: 10.2217/fmb-2019-0270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ; TREAT Consortium. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology 2018;67:1284-302. [PMID: 29083504 DOI: 10.1002/hep.29623] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
85 Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health 2019;38:81-8. [PMID: 31384519 DOI: 10.12938/bmfh.18-032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
87 López-Moreno A, Acuña I, Torres-Sánchez A, Ruiz-Moreno Á, Cerk K, Rivas A, Suárez A, Monteoliva-Sánchez M, Aguilera M. Next Generation Probiotics for Neutralizing Obesogenic Effects: Taxa Culturing Searching Strategies. Nutrients 2021;13:1617. [PMID: 34065873 DOI: 10.3390/nu13051617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Xu H, Wei Y, Ma H, Liu Y, Zhang Y, Hu L, Li J. Alterations of Gut Microbiome in the Patients With Severe Fever With Thrombocytopenia Syndrome. Front Microbiol 2018;9:2315. [PMID: 30327643 DOI: 10.3389/fmicb.2018.02315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 de Sant'Ana LP, Ribeiro DJS, Martins AMA, Dos Santos FN, Corrêa R, Almeida RDN, Eberlin MN, Maurice CF, Magalhães KG. Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice. Front Immunol 2019;10:2926. [PMID: 31998283 DOI: 10.3389/fimmu.2019.02926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
90 Guohong-liu, Qingxi-zhao, Hongyun-wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Annals of Hepatology 2019;18:796-803. [DOI: 10.1016/j.aohep.2019.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
91 Hintikka J, Lensu S, Mäkinen E, Karvinen S, Honkanen M, Lindén J, Garrels T, Pekkala S, Lahti L. Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Microbiomes with Biclustering. Int J Environ Res Public Health 2021;18:4049. [PMID: 33921370 DOI: 10.3390/ijerph18084049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Wang T, Huang S, Wu C, Wang N, Zhang R, Wang M, Mao D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. Evid Based Complement Alternat Med 2021;2021:6682581. [PMID: 33976705 DOI: 10.1155/2021/6682581] [Reference Citation Analysis]
93 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
94 Ahmed LA, Salem MB, Seif El-Din SH, El-Lakkany NM, Ahmed HO, Nasr SM, Hammam OA, Botros SS, Saleh S. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways. Eur J Pharmacol 2020;887:173461. [PMID: 32758573 DOI: 10.1016/j.ejphar.2020.173461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
95 Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Sci Rep 2020;10:9385. [PMID: 32523101 DOI: 10.1038/s41598-020-66241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
96 White LS, Van den Bogaerde J, Kamm M. The gut microbiota: cause and cure of gut diseases. Med J Aust 2018;209:312-7. [PMID: 30257633 DOI: 10.5694/mja17.01067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
98 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
99 Mehmood A, Zhao L, Wang Y, Pan F, Hao S, Zhang H, Iftikhar A, Usman M. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. Food Res Int 2021;142:110180. [PMID: 33773656 DOI: 10.1016/j.foodres.2021.110180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Ding Y, Yanagi K, Cheng C, Alaniz RC, Lee K, Jayaraman A. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. Pharmacol Res. 2019;141:521-529. [PMID: 30660825 DOI: 10.1016/j.phrs.2019.01.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
102 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
103 Kim B, Cho EJ, Yoon JH, Kim SS, Cheong JY, Cho SW, Park T. Pathway-Based Integrative Analysis of Metabolome and Microbiome Data from Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers (Basel) 2020;12:E2705. [PMID: 32967314 DOI: 10.3390/cancers12092705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Si J, Lee G, You HJ, Joo SK, Lee DH, Ku BJ, Park S, Kim W, Ko G. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. Comput Struct Biotechnol J 2021;19:5920-30. [PMID: 34849196 DOI: 10.1016/j.csbj.2021.10.032] [Reference Citation Analysis]
105 Zhou Y, Tian S, Qian L, Jiang S, Tang Y, Han T. DHA-enriched phosphatidylserine ameliorates non-alcoholic fatty liver disease and intestinal dysbacteriosis in mice induced by a high-fat diet. Food Funct 2021;12:4021-33. [PMID: 33977946 DOI: 10.1039/d0fo03471a] [Reference Citation Analysis]
106 Xie G, Wang X, Zhao A, Yan J, Chen W, Jiang R, Ji J, Huang F, Zhang Y, Lei S, Ge K, Zheng X, Rajani C, Alegado RA, Liu J, Liu P, Nicholson J, Jia W. Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes. Sci Rep 2017;7:45232. [PMID: 28345673 DOI: 10.1038/srep45232] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
107 Cerreto M, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut-Liver Axis. Nutrients 2021;13:2649. [PMID: 34444807 DOI: 10.3390/nu13082649] [Reference Citation Analysis]
108 Singh P, Kumar M, Al Khodor S. Vitamin D Deficiency in the Gulf Cooperation Council: Exploring the Triad of Genetic Predisposition, the Gut Microbiome and the Immune System. Front Immunol. 2019;10:1042. [PMID: 31134092 DOI: 10.3389/fimmu.2019.01042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
109 Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020;11:4982. [PMID: 33020474 DOI: 10.1038/s41467-020-18754-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
110 Young S, Tariq R, Provenza J, Satapathy SK, Faisal K, Choudhry A, Friedman SL, Singal AK. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatol Commun 2020;4:953-72. [PMID: 32626829 DOI: 10.1002/hep4.1519] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
111 Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines 2021;9:145. [PMID: 33546191 DOI: 10.3390/biomedicines9020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
112 Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 2021;73:126-43. [PMID: 32794259 DOI: 10.1002/hep.31523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
113 Qi L, Dai W, Kong J, Tian Y, Chen Y. Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation. J Physiol Biochem 2021. [PMID: 34302623 DOI: 10.1007/s13105-020-00782-w] [Reference Citation Analysis]
114 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
115 Marcos-Fernández R, Ruiz L, Blanco-Míguez A, Margolles A, Sánchez B. Precision modification of the human gut microbiota targeting surface-associated proteins. Sci Rep 2021;11:1270. [PMID: 33446697 DOI: 10.1038/s41598-020-80187-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
117 Sanchez-Rodriguez E, Egea-Zorrilla A, Plaza-Díaz J, Aragón-Vela J, Muñoz-Quezada S, Tercedor-Sánchez L, Abadia-Molina F. The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients 2020;12:E605. [PMID: 32110880 DOI: 10.3390/nu12030605] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
118 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
119 Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, Wahli W. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants. Biomolecules 2020;10:E1702. [PMID: 33371482 DOI: 10.3390/biom10121702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
120 Hiraga Y, Kubota T, Katoh M, Horai Y, Suzuki H, Yamashita Y, Hirata R, Moroi M. AST-120 Treatment Alters the Gut Microbiota Composition and Suppresses Hepatic Triglyceride Levels in Obese Mice. Endocr Res 2021;:1-8. [PMID: 34060951 DOI: 10.1080/07435800.2021.1927074] [Reference Citation Analysis]
121 Han Y, Jiang X, Ling Q, Wu L, Wu P, Tang R, Xu X, Yang M, Zhang L, Zhu W, Wang B, Li L. Antibiotics-mediated intestinal microbiome perturbation aggravates tacrolimus-induced glucose disorders in mice. Front Med 2019;13:471-81. [PMID: 31054103 DOI: 10.1007/s11684-019-0686-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
122 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
123 Xu S, Lin Y, Zeng D, Zhou M, Zeng Y, Wang H, Zhou Y, Zhu H, Pan K, Jing B, Ni X. Bacillus licheniformis normalize the ileum microbiota of chickens infected with necrotic enteritis. Sci Rep 2018;8:1744. [PMID: 29379124 DOI: 10.1038/s41598-018-20059-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 9.5] [Reference Citation Analysis]
124 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
125 Liu W, Luo X, Tang J, Mo Q, Zhong H, Zhang H, Feng F. A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier. Eur J Nutr 2021;60:2317-30. [PMID: 33180143 DOI: 10.1007/s00394-020-02431-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
126 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Reference Citation Analysis]
127 Wang H, Yan Y, Yi X, Duan Y, Wang J, Li S, Luo L, Huang T, Inglis B, Li X, Ji W, Tan T, Si W. Histopathological Features and Composition of Gut Microbiota in Rhesus Monkey of Alcoholic Liver Disease.Front Microbiol. 2019;10:165. [PMID: 30800107 DOI: 10.3389/fmicb.2019.00165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
128 van Trijp MPH, Schutte S, Esser D, Wopereis S, Hoevenaars FPM, Hooiveld GJEJ, Afman LA. Minor Changes in the Composition and Function of the Gut Microbiota During a 12-Week Whole Grain Wheat or Refined Wheat Intervention Correlate with Liver Fat in Overweight and Obese Adults. J Nutr 2021;151:491-502. [PMID: 33188417 DOI: 10.1093/jn/nxaa312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Ji X, Chen M, Zhao M, Song Y, Lin Y, Yin H, Zhao L. Effects of chitooligosaccharides on the rebalance of gut microorganisms and their metabolites in patients with nonalcoholic fatty liver disease. Journal of Functional Foods 2021;77:104333. [DOI: 10.1016/j.jff.2020.104333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]